There are no Focus articles on RHHBF.
There are no Transcripts on RHHBF.
at CNBC.com (Mon, 11:31AM)
at CNBC.com (Fri, 12:50PM)
at CNBC.com (Jul 23, 2014)
at CNBC.com (Jul 23, 2014)
at CNBC.com (Jul 22, 2014)
at CNBC.com (Jul 21, 2014)
Sun, Aug. 17, 8:12 AM
- Chugai Pharmaceutical (OTCPK:CHGCY) denies a rumor that surfaced Friday, which stated that Roche (OTCQX:RHHBY) was in talks to buy the 40% stake of Chugai that it does not already own for $10B.
- The media report "is not based on any announcement made by Chugai or Roche," says the Japanese company in a news release.
- Previously: Roche may gobble up the rest of Chugai
Sun, Jul. 20, 10:42 AM
- Roche (OTCQX:RHHBY) plans to continue its strategy of focusing on smaller acquisitions and partnerships rather than the big M&A deals that have been spreading across the healthcare industry.
- "We're sticking to our previous strategy. This includes targeted, small acquisitions and partnerships like the ones we have carried out in recent months," says CEO Severin Schwan. "We have to weigh up internal and external opportunities. It can't be that we have to put important internal opportunities on ice because of too-expensive acquisitions."
- The company has acquired a few small diagnostic companies this year including the recent purchase of Seragon Pharmaceuticals and Genia Technologies.
Wed, Jul. 2, 2:36 AM
- Roche (RHHBY) has announced it will buy Seragon, a breast cancer research company, for $725M. The company may pay up to another $1B based on future performance. Seragon was spun out from Aragon Pharmaceuticals last year, when the latter was purchased for $650M by Johnson & Johnson.
- Seragon is the second major acquisition for Roche in the last two months. The company bought Genia Technologies for up to $350M in in June.
Mon, Apr. 7, 7:08 AM
- Roche (RHHBF) has acquired privately held IQuum for up to $450M in a deal that will boost the Swiss company's molecular diagnostics business.
- Roche will pay $275M up front and $175M in product-related milestones.
- IQuum says its "lab-in-a-tube technology" enables "non-specialized personnel to perform more sophisticated biological sample testing in any setting." (PR)
Thu, Mar. 27, 4:26 AM
- Novartis' (NVS) Ceritinib (LDK378) reduced the size of tumors in 58% of patients in a Phase I study of those suffering from a form of lung cancer that strikes 10,000 people a year in the U.S.
- Ceritinib is the leader of a class of drugs that targets a gene known as ALK and is 20 times as effective as a drug from Pfizer (PFE) called Xalkori.
- However, patients developed resistance to Ceritinib and the median time for progression-free survival was seven months.
- The study involved 114 subjects, and while it was only Phase I, Novartis is using the results to file for FDA approval based on the drug's "breakthrough therapy designation."
- Other companies developing ALK inhibitors include Ariad Pharmaceuticals (ARIA), and Roche (RHHBF) and Japan's Chugai (CHGCY) together, while Pfizer is working on a follow-on to Xalkori. (PR)
Thu, Mar. 13, 7:25 AM
- An FDA federal advisory committee has unanimously recommended the approval of a DNA test developed by Roche (RHHBF) as the primary screening tool for cervical cancer in women.
- The product would be used alone on women aged 25 and older, and could eventually supersede the PAP test, which has been around for 60 years.
- The market for Roche's test and those of other companies is worth over $200M.
Wed, Mar. 12, 7:51 AM
- France's competition authority is investigating Novartis (NVS) and Roche over whether they conspired to prevent the use of Roche's (RHHBY) Avastin to treat vision problems in favor of the more expensive drug Lucentis, which the companies co-promote.
- The news comes after Italy last week fined the firms a combined €182.5M over similar accusations.
Mon, Mar. 10, 10:00 AM
- The WSJ profiles "pharmaceutical scouts," who, like talent-spotters in baseball "trying to pick tomorrow's big-leaguers from farm teams," search outside their companies to find drug candidates that have the potential to become blockbusters.
- In 2011, for instance, Johnson & Johnson's (JNJ) Peter Lebowitz helped his company beat competitors such as Novartis (NVS) to buy the rights to a blood-cancer drug from Pharmacyclics (PCYC) called Imbruvica.
- The treatment was eventually approved in November for a rare lymphoma and for chronic lymphocytic leukemia in February. J.P. Morgan forecasts Imbruvica will generate $1.3B in revenue for J&J in 2017.
- Half of J&J's drug pipeline is from outside the company, up from 20% in 2002.
- Other related tickers: MRK, RHHBY, BMY, SNY, CELG, GSK
Wed, Mar. 5, 9:40 AM
- Roche's (RHHBY) Lebrikizumab injection significantly lowered the rate of asthma attacks and improved lung function in a Phase IIb trial of patients with a severe form of the condition.
- In subjects with high levels of periostin, a protein that indicates a certain type of asthma and can be detected with a simple blood test, Lebrikizumab cut asthma attacks by 60% vs 5% for patients with a low level of the biomarker.
- Roche has already started two Phase III studies of Lebrikizumab and plans to file for authorization in 2016. The company has identified it as a potential blockbuster. (PR)
Tue, Mar. 4, 8:21 AM
- New Roche (RHHBF) Chairman Christoph Franz promises continuity after shareholders overwhelmingly approve his appointment.
- "This company is on track and therefore continuity is the order of the day," Franz says.
- Roche has a number of high-margin new cancer drugs and healthy profits, although it's struggling to reduce its reliance on oncology following setbacks with treatments for diabetes, "good" cholesterol and schizophrenia.
- Former CEO and outgoing Chairman Franz Humer says the firm will look at acquisitions, with the company having more strategic flexibility after accumulating cash - it generated 16.4B Swiss francs ($18.6B) in free-cash flow last year.
Mon, Mar. 3, 3:30 AM
- An independent committee has recommended that Roche (RHHBY) end a Phase III trial of its MetMab (Onartuzumab) lung-cancer treatment, as the drug didn't show "clinically meaningful efficacy."
- The aim of the study was to assess whether Onartuzumab, when given with the oral therapy Tarceva, helped previously treated patients live longer compared with those who just received Tarceva.
- Analysts had viewed MetMab as a potential blockbuster and Roche is analyzing what the setback means for the drug's development.
- Shares are -1.7% in Zurich. (PR)
Thu, Feb. 20, 10:03 AM
- Roche (RHHBF) and a group of external investigators could share raw data from two trial's of the company's Avastin drug that provide conflicting evidence about how beneficial it is for patients with a brain cancer called glioblastoma.
- Avastin didn't help patients live longer in either study, but in one of them, it does seem to have improved or maintained quality of life and brain function. That wasn't the case in the other trial.
- If Avastin can improve quality of life and brain function, says Howard Fine of the New York University Cancer Institute, "a strong argument can be made for its use as part of the initial treatment of glioblastoma, regardless of its effect on survival."
- However, such considerations would be new ground for the FDA, says Fine.
Tue, Feb. 4, 8:28 AM
- Ten major pharmaceuticals companies are getting together with the National Institutes of Health and other organizations in a five-year partnership that will look to understand the science behind Alzheimer's, Type 2 diabetes, rheumatoid arthritis and lupus.
- In an unusual move, the normally secretive participants will share scientists, tissue, blood samples and data, with the aim being to identify targets for new drugs.
- The firms involved include Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), GlaxoSmithKline (GSK), Takeda (TKPHF) and Sanofi (SNY).
- Those that haven't joined include Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
Mon, Feb. 3, 11:59 AM
- PDL BioPharma (PDLI -1.9%) says it reached agreement with Genentech and Roche (RHHBF, RHHBY) which resolves all outstanding legal disputes between the parties, including Nevada litigation and arbitration proceedings related to the audit of royalties on sales.
- Genentech will pay a fixed royalty rate of 2.125% on worldwide sales of Avastin, Herceptin, Lucentis Xolair, Kadcyla and Perjeta, rather than the previous tiered royalty rate in the U.S and the fixed rate on all ex-U.S. based manufactured and sold licensed products.
Thu, Jan. 30, 2:17 AM
- Roche's (RHHBF) 2013 net profit rose 18% to 11.4B Swiss francs ($12.7B), missing expectations of 11.62B francs.
- Core EPS +10% to 14.27 francs, falling short of consensus of 14.78 francs.
- Sales +3% to 46.8B francs topping estimates of 46.7B francs.
- Earnings were boosted by sales of Roche's oncology, immunology and ophthalmology products, as well as of its diagnostic offerings.
- Roche plans to increase its dividend by 6% to 7.80 francs a share.
- Roche forecasts that 2014 revenue will rise by a low- to mid-single-digit percentage at constant currencies and that core EPS will grow at a faster rate, with earnings boosted by sales of its biggest cancer drugs and new products. Kadcyla (breast cancer) and Gazyva (leukemia) were authorized in the U.S. last year. (PR)
Tue, Jan. 21, 7:00 AM
- Roche's (RHHBY) Bitopertin treatment for schizophrenia fell short of its main targets in two Phase III studies
- In combination with antipsychotic therapy, Bitopertin didn't significantly improve the negative symptoms of schizophrenia after 24 weeks of treatment compared with a placebo.
- Roche is continuing to carry out another Phase III study of Bitopertin for schizophrenia, and late-stage trials to assess its effect on symptoms such as hallucinations and delusions.
- The results are a particular blow, as Roche has increased its investment in neuroscience in recent years as it looks to expand beyond it core expertise of oncology.
- Shares are +0.1% in Zurich. (PR)
There are no StockTalks on this stock yet.
RHHBF vs. ETF Alternatives
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and... More
Other News & PR